Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA ...

Elrexfio is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager that binds to BCMA on multiple ... an immunomodulatory agent, and an anti-CD38 monoclonal antibody. For patients ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

AbbVie partners with Ichnos Glenmark to develop ISB 2001, a trispecific antibody for multiple myeloma, in a $1.9B licensing ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

AbbVie will be gaining rights to IGI Therapeutics’ lead candidate for oncology and autoimmune diseases in an exclusive ...

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

Glenmark Pharmaceuticals share price surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

AbbVie has entered into a $700 million licensing agreement with IGI Therapeutics to co-develop ISB 2001, a promising ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...